SK biopharmaceuticalsSK바이오팜
326030 · KOSPI · ₩326030 · SK바이오팜
₩77,800▲ ₩2,600 (3.46%)End-of-day · Oct 29, 2026 · End-of-day prices.
Income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | ₩707B | ₩548B | ₩355B | ₩246B | ₩419B |
| Cost of sales | ₩43B | ₩43B | ₩34B | ₩38B | ₩22B |
| Gross profit | ₩664B | ₩504B | ₩321B | ₩208B | ₩396B |
| Operating income | ₩204B | ₩96B | −₩38B | −₩131B | ₩95B |
| Net income | ₩253B | ₩227B | −₩35B | −₩139B | ₩65B |
| Net income to shareholders | ₩267B | ₩241B | −₩35B | −₩139B | ₩65B |
Balance sheet
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Total assets | ₩1.2T | ₩1T | ₩723B | ₩664B | ₩644B |
| Current assets | ₩683B | ₩651B | ₩489B | ₩488B | ₩471B |
| Cash and equivalents | ₩308B | ₩323B | ₩240B | ₩104B | ₩226B |
| Total liabilities | ₩372B | ₩463B | ₩402B | ₩348B | ₩199B |
| Current liabilities | ₩295B | ₩396B | ₩242B | ₩163B | ₩148B |
| Borrowings | ₩0 | ₩151B | ₩144B | ₩144B | — |
| Total equity | ₩826B | ₩574B | ₩321B | ₩317B | ₩444B |
| Shareholders' equity | ₩813B | ₩546B | ₩284B | ₩317B | ₩444B |
Cash flow
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Cash from operations | ₩176B | ₩95B | −₩94B | −₩160B | −₩93B |
| Capital spending | ₩6.9B | ₩1.4B | ₩2.4B | ₩4.9B | ₩4.3B |
| Free cash flow | ₩169B | ₩94B | −₩97B | −₩165B | −₩97B |
Consolidated where available. Amounts in won.
Also known as: SK biopharmaceuticals / SK바이오팜 / 326030 / KRX:326030
Source: KRX statistical information